azacitidine has been researched along with fibrinogen in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mukherjee, S; Ramakrishna, S; Ravichandran, R; Reddy Venugopal, J; Seitz, V; Sridhar, R; Sundarrajan, S; Wintermantel, E | 1 |
| Aisa, Y; Akimoto, M; Ito, C; Nakazato, T; Nishiyama-Fujita, Y; Sakurai, A | 1 |
2 other study(ies) available for azacitidine and fibrinogen
| Article | Year |
|---|---|
Mimicking native extracellular matrix with phytic acid-crosslinked protein nanofibers for cardiac tissue engineering.
Topics: Azacitidine; Biomarkers; Biomimetic Materials; Cell Differentiation; Cells, Cultured; Cross-Linking Reagents; Electrochemical Techniques; Extracellular Matrix; Fibrinogen; Gelatin; Hemoglobins; Humans; Mesenchymal Stem Cells; Myocardium; Nanofibers; Phytic Acid; Thy-1 Antigens; Tissue Engineering; Tissue Scaffolds; Troponin | 2013 |
The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Fibrinogen; Follow-Up Studies; Humans; Inflammation; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Retrospective Studies; ROC Curve; Serum Albumin, Human | 2021 |